The National Institute for Health and Care Excellence (Nice) has spoken of their 'disappointment' at not being able to recommend a breast cancer drug which can extend the life of terminal patients for up to 6 months.
Even with the extra flexibility that we can apply to cancer drugs, the price that Roche, the manufacturer are charging, makes it impossible to make that positive recommendation to the NHS.
The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
Lucy Kite caught up with Michelle Heaton at Ladies Day at the 2013 AEGON Classic Tennis Tournament in Birmingham, where the star talked about her support for the Ladies Fighting Breast Cancer charity, which was founded in the city for locals.
West Midlands Police have launched an investigation into a surgeon who allegedly carried out botched or unnecessary breast cancer operations at three hospitals in the West Midlands. It follows a referral from the General Medical Council, which has already suspended Ian Paterson.
Yesterday Central Tonight reported that hundreds of women who claim they had breast surgery they did not need, are calling for him to be struck off. The operations were carried out between 1994 and May last year both on the NHS and privately.